Skip to main content

Table 1 Comparison between MG relapsers and non-relapsers

From: Prospective study of stress, depression and personality in myasthenia gravis relapses

Variable Total
(n = 155)
Non-relapsers (n = 122) Relapsers
(n = 33)
p value
Age (y) 58.5 ± 14.0 58.5 ± 14.5 58.7 ± 12.3 0.9
Sex F 80 (51.6) 64 (52.5) 16 (48.5) 0.7
Disease duration (y) 10.7 ± 8.8 10.7 ± 8.6 10.8 ± 9.6 1.0
Age of onset (y) 47.8 ± 15.7 47.8 ± 16.2 47.9 ± 14.1 1.0
Generalized 128 (82.6) 97 (79.5) 31 (93.9) 0.05
MGII Score 1.4 ± 8.4 −1.6 ± 5.3 12.2 ± 7.7 < 0.0001
Thymoma 42 (27.1) 33 (27.0) 9 (27.3) 1.0
Thymectomy 87 (56.1) 67 (54.9) 20 (60.0) 0.6
AchRAb 64 (57.7) 53 (60.2) 11 (47.8) 0.2
MuSK Ab 6 (5.4) 4 (4.5) 2 (8.7) 0.5
TICS-S −5.8 ± 16.8 −6.8 ± 16.4 −1.8 ± 17.9 0.12
BDI-II −0.4 ± 5.3 −1.0 ± 5.2 1.7 ± 5.5 0.01
Potential triggers 67 (43.2) 52 (42.6) 15 (45.5) 0.8
Personal problems 26 (16.7) 17 (13.9) 9 (27.3) 0.07
Other illnesses 48 (31.0) 35 (28.7) 13 (39.4) 0.2
Medications (baseline)
 Prednisone 97 (63) 75 (61) 22 (67) 0.59
 Prednisone dose/day (mg) 13.8 ± 9.7 12.7 ± 8.3 17.2 ± 13.2 0.15
 Azathioprine 56 (41) 48 (40) 8 (24) 0.10
 Mycophenolate 26 (17) 22 (18) 4 (12) 0.40
Reduction in Immunosuppressant (baseline to follow up) 48 (31) 40 (33) 8 (24) 0.32
  1. Values are means ± SD or n (%)
  2. Statistics are calculated using unpaired two-tailed T-test for numerical data and Fisher/Chi-Square test for categorical values
  3. For MGII, TICS and BDI, values are change scores from the baseline visit
  4. Potential triggers: infections, medication change, hospital admissions
  5. CI for difference in prednisone dose: [−0.2, 0.089.1] mg (crosses 0)